Todd Davis: Pelthos Therapeutics Has Officially Launched ZELSUVMI
Todd Davis, Chief Executive Officer and Director at Ligand Pharmaceuticals, shared a post on LinkedIn:
“I want to extend my congratulations to the entire Pelthos Therapeutics team on the official commercial launch of ZELSUVMI. Our team at Ligand Pharmaceuticals recognized the potential of this at-home treatment for molluscum more than five years ago, and today’s announcement reflects the tremendous effort our teams have put into making this a reality.
This launch has the potential to benefit millions of patients and highlights the ongoing progress and significant value of our partnered programs. It also showcases the strength of our business model, which is built on innovation, strategic collaboration, and long-term value creation for our shareholders. We look forward to more exciting developments from Pelthos in the coming months.
You can read the announcement here.”
You can find more posts featuring Todd Davis in OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023